IGF-1 levels in Patients with Type 2 Diabetes Mellitus

Thipani Angela, Chrismis Novalinda Ginting, Linda Chiuman, Sahna Ferdinand Ginting

Abstract


Type 2 Diabetes Mellitus (Type 2 DM) is a metabolic disorder group with mechanisms that include hyperglycemia, insulin resistance and hyperinsulinemia. Type 2 DM has a close association with IGF-1, where the active form of the IGF-1 becomes elevated by reason of the fact that hyperinsulinemia inhibits the production of IGF-binding proteins (IGFBP) 1/IGFBP 2. The active form of IGF-1 has the ability to promote cell proliferation and inhibit apoptosis, hence becomes one of the risk factors for cancer cell growth. This was an analytical study conducted in August at the Harapan Bunda Clinic, Medan, Indonesia to determine the difference between the IGF-1 level and blood glucose level in type 2 DM patients in different age groups. Twenty subjects with Type 2 DM participated in this study and were divided based on their age into 35-50 years old or Group 1 and 51-65 year old group or Group 2. The IGF-1 levels in both groups were compared and analyzed using the T-test dependent method. Results showed that the IGF-1 and blood glucose levels were higher in Group 1 (35-50 years old) when compared to Group 2 and the difference was significant. The change in the IGF-1 level in diabetic patients cannot be determined only by the blood sugar level.


Keywords


Blood Glucose Level; IGF-1 level; Type 2 Diabetes Mellitus;

Full Text:

PDF

References


IDF. Diabetes Atlas Ninth Edition 2019. Diabetes prevalence in 2019 and projections to 2030 and 2045. Belgium: International Diabetes Federation; 2019.

Indonesian Association of Endrocrinology. Consensus management and prevention of type 2 diabetes melitus in indonesia 2015. Indonesia: PERKENI; 2015.

Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and Cancer: Two diseases with Obesity as a Common Risk Factor. Diabetes, Obesity and Metabolism. 2014; 16(2):98-100.

IARC. Latest global cancer data 2018. Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Geneva: WHO; 2018.

Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, et al. Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014; 99:1712-1721.

Rajpathak SN, He M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, et al. Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women. Diabetes. 2012;61:2248-53.

Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017;22:145-52.

Palta M, LeCaire T, Sadek-Badawi M, Herrera V, Danielson KK. The trajectory of IGF-1 across age and duration of type 1 diabetes. Diabetes Metab Res Rev. 2014;30(8):777-80.

Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in Older Adults. Diabetic Care. 2012; 35:2650-2660.

Rony S. Karakteristik Penderita Dm Rawat Inap Di Rsup H. Adam Malik Medan. 2010. Sumatera Utara: Universitas Sumatera Utara.p.28.

Heianza Y, Arase Y, Kodama S, Hsieh SH, Tsuji H, Saito K, et al. Effect of Postmenopausal Status and Age at Menopause on Type 2 Diabetes and Prediabetes in Japanese Individuals: Toranomon Hospital Health Management Center Study 17. Diabetic care. 2013; 36:4007-4013.

Liyanage IN. Diabetes mellitus and its risk factors. IJMR. 2018;4(9):114-7.

Gong Z, Kennedy O, Sun H, Wu Y, Williams GA, Klein L, et al. Reductions in serum IGF-1 during aging impair health span. Aging Cell. 2014; 13:414-415.

Clemmons DR. Metabolic Actions of IGF-I in Normal Physiology and Diabetes. Endocrinol Metab Clin North Am. 2012; 41(2):1-12.

Teppala S, Shankar A. Association Between Serum IGF-1 and Diabetes Among U.S. Adults. Diabetic Care. 2010; 33(1):2257-2258.

Lewitt MS, Dent MS, Hall K. The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus. J. Clin. Med. 2014; 3:1562-1568.

Kim TH, Chang JS, Kim H, Lee KH, Kong ID. Intense Walking Exercise Affects Serum IGF-1 and IGFBP3. Journal of Lifestyle Medicine. 2015; 5(1):21-24.

Shanmugalingam T, Bosco C, Ridley AJ, Helmerijck MV. Is there a role for IGF-1 in the development of second primary cancers? Cancer Medicine. 2016; 3354-3361.

Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Molecular Cancer. 2015; 14(43):1-11.

Su CX, Zhu HH, Zhu YM. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes. 2014; 5(3):372-377.

Yaturu S, Benyamin N, Youngberg B, Marchese M. Higher Prevalence of Prostate Cancer among Veterans with Type 2 Diabetes. Journal of Diabetes Mellitus. 2017; 7:316-319.




DOI: https://doi.org/10.15395/mkb.v53n2.2278

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



 

This Journal indexed by

                    

  


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats